Key facts
- It has raised $14.7M; the latest was Early Stage VC ($14.7M) in Feb 2026.
- Notable investors include Cancer Research Horizons, Syncona, The Francis Crick Institute.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ALTx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ALTx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ALTx Therapeutics
Developer of oncology therapeutics intended to support the treatment of cancers associated with the alternative lengthening of telomeres (ALT) pathway. The company offers research and development of targeted cancer therapeutics focused on ALT pathway biological mechanisms and novel molecular targets, enabling oncology researchers, pharmaceutical partners, and healthcare providers to transform cutting-edge science into patient impact
- Sector
- Healthcare
- HQ
- Huntingdon, United Kingdom
- Founded
- 2025
- Ownership
- Privately Held (backing)
ALTx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ALTx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ALTx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.